Home ERDERA Clinical Trial Call – Annex IV. Guidelines for Canadian Applicants

ERDERA Clinical Trial Call – Annex IV. Guidelines for Canadian Applicants

1:1

This annex explains the specific eligibility, sponsorship, funding and application requirements for Canadian applicants in the ERDERA Clinical Trial Call.

This annex sets out the eligibility criteria, sponsor requirements, funds management rules, and application steps that apply to Canadian applicants requesting funding from the Canadian Institutes of Health Research (CIHR) within the ERDERA Clinical Trial Call (ECTC). It explains who is eligible, the requirement for an EU or Norwegian legal sponsor, how CIHR and ERDERA central funding are managed for Canadian partners, and the Stage 3 submission requirements for Canadian applicants.

publication

Year of publication

2026

Author

European Rare Diseases Research Alliance (ERDERA)

ATMPs (Advanced Therapy Medicinal Products) Basket Trials Canada Clinical Development Clinical Research Networks (CRNs) Clinical Trials Data Collection and Sharing Drug Repurposing ERDERA Clinical Trial Call Genome/exome reanalysis Real-World Data (RWD)

Clinical Research ERDERA Funding International Alignment

Cyprus conference connects European research priorities with the path to rare disease treatments

10 August 2026

At the “Advancement of Treatments for Rare Diseases” conference in Nicosia, European and national policymakers joined clinicians, researchers, regulators, industry representatives and patient advocates to examine how stronger coordination can translate scientific progress into better prevention, diagnosis, treatment and access to care for people living with rare diseases.